Gene Editing Breakthroughs: New Hope for Genetic Medicine

Researchers at University College London (UCL) have reported significant advancements in the field of gene editing, citing improved efficiency and potential for curative genetic medicines. A key development in this area is the CRISPR-Cas technology, which has been widely adopted as a versatile laboratory tool. The European Medicines Agency and the Food and Drug Administration have recently approved a CRISPR-based therapy, exagamglogene autotemcel (Casgevy), administered to harvested blood.

Key Takeaways:

• The development of efficient new gene-editing techniques has improved the prospect of curative genetic medicines.
• CRISPR-Cas technology has been widely adopted as a versatile laboratory tool since its description in 2012.
• The European Medicines Agency and the Food and Drug Administration have approved the CRISPR-based therapy exagamglogene autotemcel (Casgevy).
• This therapy is administered to harvested blood.
• The research has been peer-reviewed and published in the New England Journal of Medicine.
• James W. B. Bainbridge from University College London (UCL) highlighted the potential of the adaptive immune system in single-cell organisms.
• The research provides new insights into CRISPR sequences targeting foreign DNA for cleavage by CRISPR-associated (Cas) proteins.

Statistics:

• 2012: CRISPR-Cas technology was first described by Jinek and colleagues.
• 2023: The European Medicines Agency and the Food and Drug Administration approved the CRISPR-based therapy exagamglogene autotemcel (Casgevy).
• Exagamglogene autotemcel (Casgevy) is administered to harvested blood.
• The research has been peer-reviewed and published in the New England Journal of Medicine.

Sources:

• (1) New England Journal of Medicine, 2024;390(21):2025-2027.
• NewsRx. Findings from University College London (UCL) Provide New Insights into Gene Editing (Success In Sight for Gene Editing). Biotech Week. August 7, 2024; p 182.